ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34128 results sorted by trial registration date.
  • Immunoglobulin therapy in Lung Transplant

    Intravenous immunoglobulin (IVIg) (a type of antibody) is given after lung transplantation to correct low levels in the blood of individuals. It is safe and thought to help reduce infection and rejection after transplant. This is a pilot randomised clinical trial which compares routine IVIg therapy with placebo in patients following lung transplant. Participants will be randomised in a 1 to 1 manner to receive either IVIg or placebo (Human Albumin) at week 6 post transplant and thereafter monthly for 6 months. Each participant will be followed for 1 year following transplant. Evidence of recruitment and retainment will be collected. Additionally, details of all episodes of infection, rejection, and hospitalisation will be collected. Adverse events related to the study drug and IgG levels will be collected for safety analysis.

  • A pilot physical activity intervention for middle-aged Arab-Australian women

    To our knowledge, there are no known scientifically evaluated physical activity interventions designed for middle aged Arab-Australian women. While there are a host programs and interventions designed for the general population, these are not applicable to those from culturally and linguistically diverse (CALD) backgrounds and more specifically Arab-Australian women. Due to the unique needs and requirements of each CALD group, it is important to individually tailor and target interventions to suit a specific population of interest. The aim of this study was to test the feasibility and acceptability of a 12-week culturally-tailored physical activity intervention for Arab-Australian women aged 35-64 years.

  • Specialised Fibre Supplement in Type 1 Diabetes

    Previous studies have shown specialized dietary fibre supplements can prevent type 1 diabetes in mice by altering the gut bacteria, reducing inflammation around the body and preventing the autoimmune destruction of the insulin-producing cells in the pancreas. While this fibre supplement has been used to treat other health conditions in humans, it has yet to be determined whether humans with type 1 diabetes will experience the same protection as mice. This pilot research trial therefore aims to determine whether a large clinical trial of this fibre supplement that releases high concentrations of the natural products, acetate and butyrate, is a) feasible, b) safe and c) well-tolerated in adults with established type 1 diabetes, and to (d) determine whether this supplement affects any markers of diabetes, such as changes in the gut microbiota and inflammatory markers, which would indicate the supplement would have a similar effect on type 1 diabetes protection in humans as in mice. To achieve these aims, we will conduct a pilot study in 25 adults with pre-existing type 1 diabetes consuming the dietary fibre supplement twice daily for 6 weeks, with a follow-up at 12 weeks. The supplement is an ordourless, tasteless powder that dissolves easily in cold or hot foods. Eligible participants will attend the study centre on 4 separate occasions (baseline, 3, 6 and 12 weeks) and will receive dietary counselling and an individualised plan for the times of day they take the supplement and the specific foods in their usual diet they incorporate it into. Participants will be monitored closely for changes in their blood, urine and stool pathology, their blood glucose control, insulin requirements, and any side effects or feedback on the supplement. Blood and stool samples will also be taken to at each visit to assess the preliminary efficacy of the dietary supplement and ensure the laboratory experiments are feasible for a future large clinical trial.

  • A study to evaluate the safety and pharmacokinetics (the measure of how the human body processes a substance) of EHP-101 when administered orally to healthy participants

    This research project is being conducted to investigate the safety, tolerability, and pharmacokinetics of single ascending dose and multiple ascending dose of oral EHP-101 when administered in healthy adult subjects.

  • Network of sites and ‘up-skilled’ therapists to deliver best-practice stroke rehabilitation of the upper limb.

    This study will involve the creation of a Knowledge Translation Hub and a network of specialist therapy centres in Australia. The translational hub will inform and guide stakeholders in knowledge translation, upskill therapists and establish a community of practice. The specialist therapy centres will deliver SENSe to people with stroke, and provide training to upskill therapists. The study will monitor a range of outcomes including touch sensation, functional use of the hand, and return to personally-important activities for survivors of stroke, therapist confidence to deliver SENSe, and costs to implement the service. The project has been funded by the NHMRC as a partnership grant to implement evidence into practice.

  • A randomised double-blind placebo controlled trial of cardiovascular risk reduction during bereavement

    The purpose of the present project is to investigate whether individuals in early bereavement can reduce cardiovascular risk by taking therapy (beta-blocker and aspirin)

  • De-labelling patients with antibiotic allergy in Sydney adult and paediatric hospital allergy services - toward standardisation and improved patient outcomes

    AIMS: This research project aims to collect information about the processes and outcomes of antibiotic allergy testing in a standardised way in order to improve future quality of care and outcomes for people with antibiotic allergies. The focus of this project will be on individuals with penicillin allergy labels. PARTICIPANTS: Patients who present to a hospital specialist service for assessment of penicillin allergy will be asked if they would like to participate. METHODS: Collection of information that will be routinely collected at the patient's routine penicillin allergy assessment visit and a follow up telephone call or email 8 weeks after the visit. An optional blood sample may be collected on the day to store for future research related to drug allergy. EXPECTED OUTCOMES: Improve access to antibiotic allergy delabelling services, improve the way in which appropriate advice after delabelling is provided to patients, and develop education resources for teaching and implementation of best practice into other nonhospital settings. This will provide safer and more cost effective care for all.

  • Extended Tube Feeding in Patients with Oesophageal Cancer - Pilot

    The aim of this project is to assess the impact of providing longer term tube feeding in patients with oesophageal cancer who are undergoing oesophagectomy. Who is it for? You may be eligible to join this study if you are aged 18 years or over and a have oesophageal cancer undergoing oesophagectomy at the John Hunter Hospital, NSW. Study details Study participants will be allocated by chance to either the intervention of the standard care control group. Participants in the intervention group will receive a tube feed supplying 20kCal/kg and 1g/kg protein per day (approx. 60-70% of requirements) for 12 weeks post operatively compared to a control group who will be tube fed at the same level (20kCal/kg and 1g/kg Protein) for the usual period of six weeks. On discharge all patients will be provided with standardised education regarding appropriate high energy and high protein foods and be guided through the process of reintroducing foods from puree to soft texture. It is hoped that this study will help us understand whether extending the period of tube feeding after oesophagectomy leads to better nutritional status outcomes compared to current tube feeding length.

  • Effects of yoga on combat-related Post-traumatic stress disorder (PTSD) symptoms and associated outcomes.

    The primary aim is to evaluate the effectiveness of a 6month programme of trauma-sensitive yoga (TSY), with mindfulness elements in a sample of ex-serving Defence members with a clinical diagnosis of combat-related PTSD. A secondary aim is to evaluate the effectiveness of the intervention for partners of participating ex-serving members. The study will be conducted at the Jamie Larcombe Centre by clinical staff trained in TSY. A sample of no less than 34 ex-serving Defence members will be recruited and provided with a 90minute session of TSY each week for 6 months. Data will be collected before the intervention and repeated at one, three and six months and after an additional three month follow-up. Analysis will determine change in PTSD and associated mental health symptoms in veterans. Outcomes will contribute to the emerging evidence base for yoga as an adjuvant treatment for PTSD. A convenience sample of partners will be recruited with qualitative analysis undertaken to understand their views on the effects of the programme on themselves, their partners and their relationships. The term 'partner' refers to the domestic/domiciliary partners of ex-serving Defence members. They have been included on the basis that they are in a position to offer support to the ex-serving Defence members that are the primary subjects of the study, and may also stand to benefit from participation.

  • Mouthwash as a treatment for oropharyngeal gonorrhoea

    The aim of this study is to determine whether an antiseptic mouthwash (twice a day over a 14-days period) can be used as an alternative treatment for oropharyngeal gonorrhoea without using antibiotics. If mouthwash can be used as an alternative treatment, then it would provide a possible treatment if gonorrhoea were to become multi-resistant, something that is clearly concerning the WHO and US CDC.

Tags:
  • Finding clinical trials